Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1/2 genetic mutation will reduce their levels of fear of cancer recurrence. The main questions this study aims to answer are: * Will the women who have received the adapted CBT be satisfied with it? * Will there be a significant difference in the women's fear of cancer recurrence and other variables (e.g., depression, anxiety, insomnia, fatigue, quality of life) between the com

Trial Details

NCT ID
NCT06817694
Phase
NA
Sponsor
CHU de Quebec-Universite Laval
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Cognitive-behavioral group therapy
Locations (sample)
  • Québec, Quebec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • 1\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy).
  • 2\) Be known to carry a BRCA1/2 pathogenic mutation.
  • 3\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subs…
  • 4\) Be at least 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →